Escient Pharmaceuticals

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Escient Pharmaceuticals sits in the upper quartile of US sponsors by registered trial count (#2,411 of 15,742 sponsors by registered trial count).

5 total trials none currently recruiting 4 completed early-phase tilt upper quartile by trial count

Escient Pharmaceuticals: 5 sponsored US clinical trials, none currently recruiting.

Escient Pharmaceuticals sponsors 5 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 4 completed. 0 of these trials are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Chronic Inducible Urticaria, with 1 trials.

Upper-quartile sponsor footprint

Escient Pharmaceuticals sits in the upper quartile of the sponsor corpus (#2,411 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

5 total, page 1 of 1

COMPLETED Phase 1

An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration

NCT06645704
COMPLETED Phase 2

Phase 2a, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Atopic Dermatitis

NCT06144424
TERMINATED Phase 2

Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

NCT06077773
COMPLETED Phase 1

Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

NCT06050928
COMPLETED Phase 2

Study to Evaluate EP547 in Subjects With Cholestatic Pruritus Due to Primary Biliary Cholangitis or Primary Sclerosing Cholangitis

NCT05525520

Phase Distribution

PhaseTrial count
Phase 1 2
Phase 2 3

Therapeutic Areas

Chronic Inducible Urticaria 1
Pruritus 1

How the Escient Pharmaceuticals early-phase archive is shaped

5 indexed studies, none listed as recruiting (0% open); 4 completed (80%).

Phase mix: 0 late (III/IV) vs 5 early (I/II) (early-phase heavy).

Top condition: Chronic Inducible Urticaria (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Escient Pharmaceuticals: archived-pipeline peers nationwide

Peers matched on 5 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Escient Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%5%10%15%20%25% Total trials Recruiting share Escient Pharmaceuticals4YouandMeAbbott Rapid DxAccess Business GroupAcera Surgical10xBio22nd Century Group23andMe3-C Institute for Social Development
Escient Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Escient Pharmaceuticals sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 5 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Escient Pharmaceuticals page

5 registered trials is a research-attention snapshot, not an endorsement of Escient Pharmaceuticals or any single study.

  • None of Escient Pharmaceuticals's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Chronic Inducible Urticaria is the condition Escient Pharmaceuticals studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Chronic Inducible Urticaria trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Escient Pharmaceuticals pipeline card: 5 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.